The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2025 | SIERRA: safety of durvalumab and tremelimumab in Asian patients with uHCC
Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, South Korea, discusses safety outcomes among Asian patients with unresectable hepatocellular carcinoma (uHCC) treated with first line STRIDE (single tremelimumab regular interval durvalumab) in the Phase IIIb SIERRA study (NCT05883644). Overall rates of treatment-related adverse events were consistent across clinical subgroups, with manageable immune-related toxicity and limited treatment discontinuation. This interview took place at 2025 European Society for Medical Oncology (ESMO) Asia Congress in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The phase 3B trials of investigating the safety and efficacy of the STRIDE regimen, which is now the standard first-line therapy in the sector of HCC, for mainly targeting the patients who were not eligible for the original hepatolysis trial. So in this study’s main target population is a patient with poor liver function, Child-Pugh 7 or 8, and all the patients with good liver function but bad performance status, equal performance status too...
The phase 3B trials of investigating the safety and efficacy of the STRIDE regimen, which is now the standard first-line therapy in the sector of HCC, for mainly targeting the patients who were not eligible for the original hepatolysis trial. So in this study’s main target population is a patient with poor liver function, Child-Pugh 7 or 8, and all the patients with good liver function but bad performance status, equal performance status too. And the other patient group is the patient with main portal vein invasion. We call it the BP4 invasion. These patients should bear a poor prognosis. And these all three categories of patients were not included in the original HIMALAYA trial. So, this year’s study, in this study, the early safety outcomes of the STRIDE regimen for these patients with poor prognosis were presented. Original global study population data was presented as last year, and this study, in this study, Asian data was presented. And in general, there is no new safety profile of the STRIDE in this patient population, and there is no difference in terms of the global versus Asian patient population safety profile. So this study, this STRIDE study, showed that STRIDE has a manageable safety profile in patients with VP4 invasion or poor performance status, as well as Child-Pugh liver function. But we need more mature data for this patient population.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
